Literature DB >> 17188609

Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing.

Jennifer M Barker1, Kim McFann, Leonard C Harrison, Spiros Fourlanos, Jeffrey Krischer, David Cuthbertson, H Peter Chase, George S Eisenbarth.   

Abstract

OBJECTIVE: To determine the relationship of intravenous (IVGTT) and oral (OGTT) glucose tolerance tests abnormalities to diabetes development in a high-risk pre-diabetic cohort and to identify an optimal testing strategy for detecting preclinical diabetes. STUDY
DESIGN: Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) randomized subjects to oral (n = 372) and parenteral (n = 339) insulin prevention trials. Subjects were followed with IVGTTs and OGTTs. Factors associated with progression to diabetes were evaluated.
RESULTS: Survival analysis revealed that higher quartiles of 2-hour glucose and lower quartiles of first phase insulin response (FPIR) at baseline were associated with decreased diabetes-free survival. Cox proportional hazards modeling showed that baseline body mass index (BMI), FPIR, and 2-hour glucose levels were significantly associated with an increased hazard for diabetes. On testing performed within 6 months of diabetes diagnosis, 3% (1/32) had normal FPIR and normal 2-hour glucose on OGTT. The sensitivities for impaired glucose tolerance (IGT) and low FPIR performed within 6 months of diabetes diagnosis were equivalent (76% vs 73%).
CONCLUSIONS: Most (97%) subjects had abnormal IVGTTs and/or OGTTs before the development of diabetes. The highest sensitivity is achieved using both tests.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17188609      PMCID: PMC1868416          DOI: 10.1016/j.jpeds.2006.09.033

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  22 in total

1.  Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria.

Authors:  C J Greenbaum; D Cuthbertson; J P Krischer
Journal:  Diabetes       Date:  2001-02       Impact factor: 9.461

2.  Standardization of IVGTT to predict IDDM.

Authors:  P J Bingley; P Colman; G S Eisenbarth; R A Jackson; D K McCulloch; W J Riley; E A Gale
Journal:  Diabetes Care       Date:  1992-10       Impact factor: 19.112

3.  First-phase insulin release in normal children.

Authors:  H F Allen; B W Jeffers; G J Klingensmith; H P Chase
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

4.  Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients.

Authors:  P Vardi; L Crisa; R A Jackson
Journal:  Diabetologia       Date:  1991-02       Impact factor: 10.122

5.  Ten-year follow-up study of islet-cell antibodies and childhood diabetes mellitus.

Authors:  G J Bruining; J L Molenaar; D E Grobbee; A Hofman; G J Scheffer; H A Bruining; A M de Bruyn; H A Valkenburg
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

6.  Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.

Authors:  C F Verge; R Gianani; E Kawasaki; L Yu; M Pietropaolo; R A Jackson; H P Chase; G S Eisenbarth
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

7.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

8.  Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives.

Authors:  P J Bingley; M R Christie; E Bonifacio; R Bonfanti; M Shattock; M T Fonte; G F Bottazzo; E A Gale
Journal:  Diabetes       Date:  1994-11       Impact factor: 9.461

9.  Islet-cell antibodies in juvenile diabetes mellitus of recent onset.

Authors:  R Lendrum; G Walker; D R Gamble
Journal:  Lancet       Date:  1975-04-19       Impact factor: 79.321

10.  Ten-year prognosis of impaired glucose tolerance in siblings of patients with insulin-dependent diabetes.

Authors:  A L Rosenbloom; S S Hunt; E K Rosenbloom; N K Maclaren
Journal:  Diabetes       Date:  1982-05       Impact factor: 9.461

View more
  16 in total

1.  To boldly go--or to go too boldly? The accelerator hypothesis revisited.

Authors:  E A M Gale
Journal:  Diabetologia       Date:  2007-08       Impact factor: 10.122

Review 2.  Metabolic abnormalities in the pathogenesis of type 1 diabetes.

Authors:  Shuyao Zhang; Clayton E Mathews
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

3.  Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.

Authors:  Wei Hao; Alyssa Woodwyk; Craig Beam; Henry T Bahnson; Jerry P Palmer; Carla J Greenbaum
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

4.  Biphasic decline of β-cell function with age in euglycemic nonobese diabetic mice parallels diabetes onset.

Authors:  Sirlene R Cechin; Omar Lopez-Ocejo; Darla Karpinsky-Semper; Peter Buchwald
Journal:  IUBMB Life       Date:  2015-06-22       Impact factor: 3.885

5.  German new onset diabetes in the young incident cohort study: DiMelli study design and first-year results.

Authors:  Leonore Thümer; Kerstin Adler; Ezio Bonifacio; Frank Hofmann; Manfred Keller; Christine Milz; Axel Munte; Anette-Gabriele Ziegler
Journal:  Rev Diabet Stud       Date:  2010-11-10

6.  Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.

Authors:  George S Eisenbarth
Journal:  Diabetes       Date:  2010-04       Impact factor: 9.461

Review 7.  The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1.

Authors:  Jay M Sosenko; Jay S Skyler; Kevan C Herold; Jerry P Palmer
Journal:  Diabetes       Date:  2012-06       Impact factor: 9.461

8.  Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis.

Authors:  Ping Xu; Craig A Beam; David Cuthbertson; Jay M Sosenko; Jay S Skyler; Jeffrey P Krischer
Journal:  Diabetes Care       Date:  2012-07-11       Impact factor: 19.112

9.  Progressive erosion of β-cell function precedes the onset of hyperglycemia in the NOD mouse model of type 1 diabetes.

Authors:  Diego Ize-Ludlow; Yaima L Lightfoot; Matthew Parker; Song Xue; Clive Wasserfall; Michael J Haller; Desmond Schatz; Dorothy J Becker; Mark A Atkinson; Clayton E Mathews
Journal:  Diabetes       Date:  2011-06-09       Impact factor: 9.461

10.  Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1.

Authors:  Jay M Sosenko; Jerry P Palmer; Lisa Rafkin-Mervis; Jeffrey P Krischer; David Cuthbertson; Jeffery Mahon; Carla J Greenbaum; Catherine C Cowie; Jay S Skyler
Journal:  Diabetes Care       Date:  2009-06-01       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.